tradingview.comNov 10

JP Morgan maintains Cencora at Overweight, raises price target to $413 from $390

JP Morgan kept Cencora's rating at Overweight and increased its price target to $413 from $390, suggesting a 19.4% upside from the Nov 9 close of $345.76. Recent analyst price targets for Cencora range from $375 to $405.

Original reporting

tradingview.com

Published Nov 10, 2026, 4:38 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 10, 2026, 4:43 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

JP Morgan maintains Cencora at Overweight, raises price target to $413 from $390 — source image — Source · tradingview.com

Decision brief

The 30-second read

High

Why it matters

The upgrade signals confidence in Cencora's earnings outlook and may attract new buying.

Market read

Analyst upgrade could drive short-term buying pressure in Cencora stock.

What to watch

Potential regulatory or supply-chain risks for Cencora are not addressed.

Relevance 7/10Novelty 8/10Timing: today

Background

JP Morgan's analyst team upgraded Cencora to Overweight and increased its price target.

Market effects

Sector

Positive sentiment may lift other pharmaceutical distributors.

Regional

U.S. healthcare sector could see modest gains.

Global

Limited to U.S. markets; no broad macro effect.

Counterpoint

What could challenge this read

Some investors may view the target raise as already priced in, limiting upside.

Key entities

Analyst
JP Morgan
Investment bank providing the rating and price target.
Company
Cencora
Pharmaceutical distribution company.

Read at source ← All news

$CORMedAI 8/10

Cencora Inc (COR) (Q4 2026) Earnings Call Highlights: Record Fiscal 2026 Results

Cencora Inc. (COR) reported record fiscal 2026 results, with adjusted operating income growth of 14% and adjusted diluted EPS of $17.97, up 12%. The company introduced a new operating model, expanded its MSO platform through acquisitions, and expects specialty distribution revenue to reach $100 billion in fiscal 2027. However, fiscal 2027 guidance includes headwinds from divestitures and FX impacts, with adjusted EPS growth of 8-10%.

finance.yahoo.comNov 5

$CORHighAI 9/10

Key facts: Cencora FY26 growth; OneOncology margins; Leerink target up

Cencora reported fiscal 2026 revenue of $337.4B, up 5%, and adjusted EPS of $17.97, up 12.3%. The company forecast fiscal 2027 EPS of $19.40–$19.75 and raised its dividend by 10%. OneOncology acquisition improved margins, partly offset by lower-margin GLP-1 sales. Leerink Partners increased its price target to $405 from $388.

tradingview.comNov 5

$CORHighAI 8/10

What Cencora (COR) Said on Its Q4 Earnings Call

Cencora (COR) reported a 5% revenue increase to $337B and 12% EPS growth to $17.97 for FY2023. The company expects 3-5% revenue growth and 4-6% operating income growth for FY2027, with specialty segments driving higher growth. Cencora plans $1B in share repurchases and a 10% dividend increase, while completing key acquisitions in oncology and retina.

finance.yahoo.comNov 5

HighAI 8/10

Cencora, Inc. Q4 2026 Earnings Call Summary

Cencora, Inc. reorganized into two segments—Specialty Pharmaceutical and Provider Services, and Pharmaceutical Distribution and Services—to focus on high-growth areas. The company expects specialty distribution revenue to reach $100 billion in fiscal 2027, with long-term growth targets of mid-single digits for Distribution and mid-teens for Specialty. Cencora plans $1.25 billion in share repurchases and $1 billion in capital expenditures.

finance.yahoo.comNov 4

$CORHighAI 8/10

Cencora Q4 FY2026 slides: specialty drives 22% operating income surge

Cencora (NYSE:COR) reported Q4 FY2026 revenue of $88.4B (+5.5% YoY) and adjusted operating income of $1.2B (+22.1% YoY), driven by specialty pharmaceutical growth. Full-year revenue was $337.4B (+5.0% YoY), with adjusted operating income up 14.0%. The company raised its dividend by 10% and provided FY2027 guidance of 3-5% revenue growth and 4-6% operating income growth.

investing.comNov 4

$CORMed

Cencora, Inc. (COR): Fiscal Year Ended September 30, 2026 Revenue First Quarter Second Quarter Third Quarter Fourth Quarter Fiscal Year (As Revised) (As Revised)

Cencora, Inc. (COR) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 CENCORA, INC. SUMMARY REPORTABLE SEGMENT INFORMATION (in thousands) (unaudited) The following illustrates revised reportable segment revenue information for the periods indicated: Fiscal Year Ended September 30, 2026 Revenue First Quarter Second Quarter Third Quarter

SEC EDGAR 8-KNov 4